Garcinia forbesii King leaf extract protects against renal tubular injury in ischemia- reperfusion injury via IL-18 and oxidative stress reduction

Read full text Summarise with VIRAT
Authors: Azma Rosida, Nia Kania, Mohammad Rudiansyah, Fujiati, Triawanti, Ika Kustiyah Oktaviyanti, Roselina Panghiyangani, Nur Arfian
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Purpose: To evaluate the protective effects of Garcinia forbesii King leaf extract against renal tubular injury induced by Renal ischemia–reperfusion injury (IRI) and to assess its association with inflammatory and oxidative stress markers, including interleukin-18 (IL-18), superoxide dismutase 2 (SOD2), and malondialdehyde (MDA). Methods: Male Wistar rats were subjected to renal IRI and treated with Garcinia forbesii King leaf extract at doses of 2.5, 25, and 250 mg/kg. Renal IL-18 levels, SOD2 expression, serum MDA levels, and histopathological tubular injury scores were evaluated. Results: Renal IL-18 levels were significantly increased in IRI group compared with the sham-operated group. Treatment with Garcinia forbesii King leaf extract at doses of 25 and 250 mg/kg significantly reduced renal IL-18 levels. The medium dose (25 mg/kg) significantly increased renal SOD2 expression and reduced serum MDA levels. Histopathological analysis showed that low- and medium-dose treatments attenuated renal tubular injury, whereas the high dose did not provide additional histological protection. Conclusion: Garcinia forbesii King leaf extract exerts nephroprotective effects against IRI-induced renal injury, likely through modulation of inflammatory responses and oxidative stress.

Fields of Study & Subjects

Acute Kidney Injury Research Chemotherapy-induced organ toxicity mitigation Medicinal Plant Research

Publication details

Journal / source
Tropical Journal of Pharmaceutical Research
Volume
25
Issue
2
Pages
205–212
Publication date
24 March 2026
Language
EN